Tag: Fisher & Paykel Healthcare
Fisher & Paykel Healthcare reports cyber incident
October 22, 2026HME News Staff
AUCKLAND, New Zealand – Fisher & Paykel Healthcare has been made aware of unauthorized and unlawful access to two employee email accounts and a subset of company files.
The company says it immediately activated its response protocols to contain the incident and investigate the nature and extent of the activity.
“There has been no impact to the company’s products, manufacturing operations or supply chain, and its ability to supply and support customers and patients continues...
F&P Healthcare sells part of land for second campus in New Zealand
October 6, 2026HME News Staff
AUCKLAND, New Zealand – Fisher & Paykel Healthcare has entered into an agreement to sell 13 hectares of its 105-hectare site on Karaka Road in Drury, New Zealand, to Health New Zealand at a purchase price of $45.3 million. Health NZ intends to use the land to develop a future hospital facility to serve the growing South Auckland population. Fisher & Paykel Healthcare will retain the remaining land for the development of its planned second campus in New Zealand. “We have worked closely...
F&P Healthcare updates financial outlook for 2027
August 24, 2026HME News Staff
AUCKLAND, New Zealand – Fisher & Paykel Healthcare now expects revenue of about $1.24 billion and net profit after tax of about $280 million for the first half of the 2027 financial year, representing about 14% and 24% growth, respectively, compared to the prior-year period. It now expects operating revenue to be about $2.47 billion to $2.57 billion and net profit after tax to be about $525 million to $565 million for the 2027 financial year. “We have had a strong start to our first...
Sleep therapy growth at inflection point
June 10, 2026HME News Staff
Sleep therapy is expanding across new channels, technologies and care settings, creating more ways than ever to diagnose and treat obstructive sleep apnea – and giving providers new opportunities to shape the patient journey, despite its growing complexity, industry experts say.
“Demand remains strong because obstructive sleep apnea continues to be significantly underdiagnosed, but the pathway into therapy is changing rapidly,” said Robin Randolph, senior vice president of sales...
F&P fields questions on mask pipeline, tariff impact
May 27, 2026Liz Beaulieu, Editor
AUCKLAND, New Zealand – Analysts pressed Fisher & Paykel Healthcare executives during a recent earnings call on the company’s lack of new full-face mask launches for obstructive sleep apnea (OSA), even as other product categories continue to gain traction.
Analyst Ben Crozier described the full-face mask category as “a bit of a headwind” for F&P, noting it has been offset by more recent and frequent launches in other categories, including the F&P Solo (nasal), F&P Nova...
F&P sees high, single-digit boost from recent mask launches
May 26, 2026HME News Staff
AUCKLAND, New Zealand – Fisher & Paykel Healthcare reported revenue of $802.7 million for the 2026 financial year for its Homecare product group, an 8% increased compared to the previous year.
Revenue from obstructive sleep apnea (OSA) masks was up 7%.
“Our latest mask ranges, the F&P Solo and F&P Nova, continued to drive OSA mask growth,” said Lewis Gradon, managing director and CEO. “Our newest offering, the F&P Nova Nasal, was launched in the United...
Fisher & Paykel Healthcare raises guidance
February 23, 2026HME News Staff
AUCKLAND, New Zealand – Fisher & Paykel Healthcare now expects full-year operating revenue to be about $2.3 billion, and net profit after tax to be in the range of about $450 million to $470 million. Previously, the company said it expected operating revenue in the range of about $2.17 billion to $2.27 billion and full-year net profit after tax of about $410 million to $460 million. “While relative seasonal respiratory hospitalizations in...
F&P Healthcare reports ‘strong result’ in first half
November 26, 2025HME News Staff
AUCKLAND, New Zealand – Fisher & Paykel Healthcare reported total operating revenue of $1.09 billion for the first half of the 2026 financial year, a 14% increase year over year. Net profit after tax was $213 million, a 39% increase.
“Our people have continued to work closely with clinicians, progress work on new products and deliver a range of efficiency improvements across the business,” said Managing Director and CEO Lewis Gradon. “This is a strong result against...
In brief: CGM overpayments, Abbott device correction, veterans’ Parkinson’s risk
November 26, 2025HME News Staff
WASHINGTON – Medicare payments for continuous glucose monitors (CGMs) and supplies exceeded supplier acquisition costs by $377 million (or 69%) and their total estimated costs by $70 million (or 8%) in one year, according to a new report from the Office of Inspector General (OIG).
Medicare Part B payments for CGMs and supplies rose from $109 million in 2018 to $1.3 billion in 2023. Of note, CMS expanded CGM coverage to beneficiaries with Type 2 diabetes in 2023
The OIG compared...
In brief: CMS's scrutiny, F&P's strength, Resmed's recognition
August 22, 2025HME News Staff
WASHINGTON – The Centers for Medicare & Medicaid Services (CMS) has launched an oversight initiative to ensure that enrollees in Medicaid and the Children’s Health Insurance Program (CHIP) are U.S. citizens, U.S. nationals, or have a satisfactory immigration status.
CMS will begin providing states with monthly enrollment reports identifying individuals whose citizenship or immigration status could not be confirmed through federal databases, including the Department of Homeland...